Morning Briefing
Summaries of health policy coverage from major news organizations
Newspapers Examine Concerns Surrounding Possible FDA Approval Of Truvada For PrEP
The New York Times and the Financial Times examine concerns expressed by AIDS activists and members of an FDA panel that last week recommended Gilead Sciences' antiretroviral drug Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus. According to the New York Times, "Such a pill has long been a goal of research, something that might help stem a global epidemic that is still causing two million new worldwide cases each year, including 50,000 in the United States" (Grady, 5/14). The Financial Times says some have concerns over the real world efficacy of the drug; whether its approval would encourage reckless behavior, such as not using condoms; side effects that might require additional treatment; the development of drug-resistant HIV strains; and the cost of the drug.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
